Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Sun Pharma to buy Organon for $11.75B

Digest more
Top News
Overview
Highlights
Fierce Pharma · 13h
Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) of women’s health leader Organon. With its $11.75 billion buyout, Sun has picked up a drugmaker that matched the $6.

Continue reading

 · 17h · on MSN
Sun Pharma to buy US drugmaker Organon for $11.75 billion in India's largest pharma deal
New Jersey Business Magazine · 9h
Sun Pharma Signs Definitive Agreement to Acquire Organon
 · 8h
Organon gives Sun Pharma scale and reach, but challenge lies in integration, execution
Sun Pharma has acquired Organon & Co for $11.75 billion.

Continue reading

Forbes India · 15h
Sun Pharma’s $11.75 billion buy: Is the Organon deal valuation fair?
 · 17h
Major outbound deals by Indian companies
 · 22h
Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details
Sun Pharma rallied after the company entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all-cash transaction with an e...

Continue reading

 · 23h
Buzzing stocks: Axis Bank, RBL Bank shares down pos- Q4 earnings; Sun Pharma gains on Organon acquisition
Fortune India · 1d
Sun Pharma shares jump 5% after $11.75 billion Organon acquisition deal
31mon MSN

OxyContin maker Purdue Pharma's criminal sentence could be the last step before company dissolves

OxyContin maker Purdue Pharma could be dissolved and replaced by a company focused on the public good by the end of the week, as a massive legal settlement resolving thousands of lawsuits is set to take effect.
3d

Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai – A Platform to Conquer Rare Cancers

CEO Panna Sharma to Lead Live, Unscripted Platform Walkthrough in Two Interactive Sessions on April 30, 2026 - Open to
Pharmaceutical Technology
10h

Pharma Meets AI Conference 2026: AI in pharma begins delivering measurable ROI

AI tools that slash time spent on administration prove their worth and free up pharma workers for higher value tasks.
6d

Judge postpones OxyContin-maker Purdue Pharma’s sentencing to let opioid victims attend in person

A judge has rescheduled a hearing in which she is expected to sentence OxyContin maker Purdue Pharma to forfeit $225 million to the U.S. government. U.S.
11hon MSN

Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs

Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
15h

Sun Pharma Share Price Highlights: Sun Pharma Stock Price History

Welcome to the Sun Pharma Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent stocks in the market. Stay on top of the game with our comprehensive coverage,
14hon MSN

Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million

By Puyaan Singh April 27 (Reuters) - Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday. The deal adds more than 120 treatments,
14h

Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This Stock

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Ascendis Pharma A/S (NASDAQ:ASND) ranks 9th on this list. The primary catalyst for hedge fund interest in Ascendis Pharma A/S (NASDAQ:ASND) stock over the past few weeks is the FDA approval of YUVIWEL for children with achondroplasia.
  • Privacy
  • Terms